Dr. Andrea Bild trained as a pharmacologist with a specialization in genomics and cancer cell biology. Her research program has established the development and clinical translation of a systems biology framework for personalized medicine genomics. Specifically, her research has enabled 1) investigations of signaling pathways and networks in a physiologically relevant setting: patient tumors; 2) algorithms to personalize matching of effective drugs to patients; and 3) systems-guided clinical trials with novel therapeutic strategies. Dr. Bild has also developed and founded the Genome Science Program at the University of Utah in order to train students and scientists in genomics and systems biology as well as create a rich collaborative structure for faculty across campus with expertise in this field.
Andrea Bild, Ph.D., serves as professor in the Division of Molecular Pharmacology within the Department of Medical Oncology & Therapeutics Research. She comes to City of Hope from the University of Utah, where she was an associate professor and director of Genome Sciences.
Dr. Bild obtained her B.S. at the University of Florida, her Ph.D. at the University of Colorado, and carried out her postdoctoral training at Duke University.
Dr. Bild’s research program focuses on cancer, and uses large-scale translational genomic and pharmacological studies to interrogate and treat tumor heterogeneity and evolution to refractory states. She has led multiple collaborative groups with the goal of characterizing and treating cancer.
As a member of the National Cancer Institute’s Cancer Systems Biology Consortium and principal investigator of multi-institutional grants, her team focuses on the development and application of multi-omic tools in the clinic for cancer prevention and treatment. With clinician collaborators, Dr. Bild’s team has initiated and carried out multiple clinical trials that use systems biology and genomic characterization of patient tumors to prevent cancer resistance and progression.
Dr. Adey started out in biotechnology development at the University of Texas where he researched alternative applications of microarrays in the lab of Andrew D. Ellington, Ph.D. He later served as interim director of the UT microarray core facility and then helped set up the UT genome sequencing and analysis facility in the early days of next generation sequencing. He then completed his doctoral studies in the Molecular and Cellular Biology Program at the University of Washington in the lab of Jay Shendure, M.D., Ph.D. in the Genome Sciences Department.
Previous research highlights include pioneering a novel transposase-based method for rapid, low-input DNA sequencing library construction, which I extended to the genome-wide analysis of DNA methylation. I also applied long-range sequencing methods to produce the first haplotype resolved genome and epigenome of an aneuploid cell line, HeLa, where I investigated the role of haplotype and copy number on the epigenetic and transcriptional landscape. I plan to continue my focus on the development and implementation of novel strategies to investigate the epigenome with high precision. This includes single cell approaches to disambiguate epigenetic and transcriptional heterogeneity within populations of cells which is typically obscured by bulk preparation methods. This work will provide insight into the dynamic regulatory landscape of cells and may reveal functional and targetable subpopulations in the context of disease intervention.
Evan Eichler, Ph.D., is a Professor and Howard Hughes Medical Institute Investigator in the Department of Genome Sciences, University of Washington School of Medicine. He graduated with a B.Sc. Honours degree in Biology from the University of Saskatchewan, Canada, in 1990. He received his Ph.D. in 1995 from the Department of Molecular and Human Genetics at Baylor College of Medicine, Houston, Texas. After a Hollaender postdoctoral fellowship at Lawrence Livermore National Laboratory, he joined the faculty of Case Western Reserve University in 1997 and later the University of Washington in 2004. He was a March of Dimes Basil O’Connor Scholar (1998–2001), appointed as an HHMI Investigator (2005), awarded an AAAS Fellowship (2006) and the American Society of Human Genetics Curt Stern Award (2008), and elected to the National Academy of Sciences (2012) and the National Academy of Medicine (2017). He is an editor of Genome Research and has served on various scientific advisory boards for both NIH and NSF. His research group provided the first genome-wide view of segmental duplications within human and other primate genomes and he is a leader in an effort to identify and sequence normal and disease-causing structural variation in the human genome. The long-term goal of his research is to understand the evolution and mechanisms of recent gene duplication and its relationship to copy number variation and human disease.
Gosia Trynka strongly believes that interdisciplinary approaches are essential to achieve meaningful insights into biological processes. The combination of molecular techniques, genomic assays, and computational methods that we develop and apply to study the immune system is a reflection of my own career path through several disciplines within biology and genetics.
With a backround in molecular biology, Gosia became interested in medical and population genetic approaches to study genetic determinants for immune related diseases. Gosia joined Prof. Cisca Wijmenga’s group where Gosia was a co-lead analyst for the genome-wide association study (GWAS) and an Immunochip study for coeliac disease (an immune disease of the small intestine resulting from intolerance to gluten). These studies resulted in identification of tens of disease risk loci and pointed to strong shared genetic backround between celiac disease and a range of other common immune conditions, including type-1 diabetes, rheumatoid arthritis, and inflammatory bowel disease.
Despite the great success in mapping disease risk variants, Gosia was disappointed by the limited insights that we gained in understanding biology of complex immune diseases. Gosia therefore carried out my postdoctoral research at Brigham and Women’s Hospital, Harvard Medical School and Broad Institute where she joined Dr. Soumya Raychaudhuri’s and Dr. Robert Plenge’s groups. Gosia invested my time in developing statistical methods that allow translation of GWAS associations into biological functions. By integrating disease-associated variants with functional genomics data, these approaches pointed to specific cell types being relevant in the pathogenesis of numerous complex traits, including immune diseases. Gosia ‘s group at the Sanger Institute continuous with experimental and computational efforts to further map and translate immune disease genetic variants to function.
Dr. Law received her Bachelor’s degree in Biochemistry and Biophysics from Oregon State University in 2001 and her Ph.D. degree in Biochemistry from the Johns Hopkins University School of Medicine in 2006 where she investigated RNA editing in Trypanosome brucei in the Sollner-Webb laboratory. Dr. Law’s post-doctoral research in the laboratory of Dr. Steven E. Jacobsen at the University of California, Los Angeles focused on understanding the roles of small RNAs in targeting DNA methylation and gene silencing in Arabidopsis thaliana and was supported by a Ruth L. Kirschstein National Research Service Award from the National Institute of Health. In September of 2012, Dr. Law joined the Plant Biology program at the Salk Institute for Biological Sciences as an Assistant Professor where she continues to focus on epigenetics and other chromatin-based processes. In 2015, Dr. Law received the Hearst Foundation Developmental chair and was named a Rita Allen Foundation Scholar and in 2018 Dr. Law was selected as a Newsweek “Women of the Future” Nominee.
Michael Schatz, Bloomberg Distinguished Associate Professor of Computer Science and Biology at Johns Hopkins University, is among the world’s foremost experts in solving computational problems in genomics research. His innovative biotechnologies and computational tools to study the sequence and function of genomes are advancing the understanding of the structure, evolution, and function of genomes for medicine – particularly autism spectrum disorders, cancer, and other human disease – and agriculture.
Schatz, who founded and directs the Schatz Lab, has created many of the most widely used methods and software to assemble the full genetic material for a single person or a species, including:
NGMLR and Sniffles are long-read sequencing analysis methods to study the longer fragments of DNA, a breakthrough that may yield critical information about how cancer genomes evolve. Genomes in malignant tumors often house sections of chromosomes that are deleted, duplicated or fused together. By examining an unstable genome, Schatz identified almost 20,000 structural alterations – changes previously missed by other researchers when examining shorter DNA fragments.
Scalpel, the leading genetic variants discovery tool, to identify and analyze mutations in autism spectrum disorders and somatic mutations (or post-conception DNA alterations) in cancer genomes, including pancreatic cancers.
GECCO (Genomic Enrichment Computational Clustering Operation), a novel algorithm to study complex non-coding and structural variations in genomes, through which his lab identified recurrent non-coding somatic mutations (DNA alterations that occur post-conception) in pancreatic cancer, including some that substantially changed survival outcomes.
Ginkgo, a computational tool for single cell copy number profiling in heterogeneous tumors to study the progression of primary and metastatic breast tumors and adult acute myeloid leukemia.
New computational methods including FALCON and Assemblytics for assembling and analyzing the genomes of different species using single molecule sequencing, especially plant and animal species, to study their evolution and adaption.
CloudBurst and Crossbow, the first published algorithms to use cloud computing technologies in genomics for mapping and variant discovery.
Schatz holds appointments in the Department of Computer Science at the Whiting School of Engineering and in the Department of Biology at JHU Krieger School of Arts and Sciences. He also serves as a cancer prevention and control program member for the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Prior to joining JHU in 2016, he spent six years at the Cold Spring Harbor Laboratory (CSHL) where he co-led the Cancer Genetics & Genomics Program in the CSHL Cancer Center. Schatz remains a CSHL adjunct associate professor of Quantitative Biology.
Recent awards include the Alfred P. Sloan Foundation Fellowship, Computational and Evolutionary Molecular Biology, in 2015, and the NSF CAREER Award in 2014. Schatz’s earlier honors are Young Investigator of the Year, Genome Technology (2010) and the twice-awarded Winship Herr Award for Excellence in Teaching, Watson School for Biological Science. His leadership of the computational biology field includes founding in 2012 a new, interdisciplinary CSHL conference on Biological Data Science, as well as a regular member of the program committees to Genome Informatics, RECOMB, ISMB, WABI, and several other top conferences.. Schatz serves on the editorial boards of Genome Biology, GigaScience, and Cell Systems, and he has served as a reviewer for Nature, Cell, Science,Nature Biotechnology, Nature Methods, Genome Research, Genome Medicine, and Bioinformatics. His innovative discoveries have been featured in The New York Times, The Washington Post, and Wired.
He holds a BS in Computer Science from Carnegie Mellon University (2000) and an MS (2008) and PhD (2010), both in Computer Science, from the University of Maryland, College Park.